login
register
Home
Getting Started
ChartMill Overview
Growth Traders
Technical Swing Traders
Long Term Investors
Tools
Stock Screener
Stock Charts
Full Screen Stock Charts
Market Monitor
Sectors
Earnings
Analyzer
Insider Trading
Up- and Downgrades
Stock Market
Top Gainers and Losers
New 52 Week High and Low
Gap Up and Gap Down
Most Active
Premarket Movers
After-Hours Movers
Earnings Calendar
USA Market Overview
Canada Market Overview
Europe Market Overview
Trading Ideas
News
Blog
Documentation
Documentation Center
Videos
Indicators
Properties
Screener Market data
Popular Articles
Bull Flags
Relative Strength
Pocket Pivots
Support and Resistance
RSI Indicator
MACD Indicator
Piotroski F-score
Squeeze Plays
Weinstein
Technical Breakout Setups
Trading Tips
Premarket Movers
Gap Up Stocks
Best Dividend Stocks
Bullish Engulfing Pattern
Ascending Triangle Pattern
Swing Trading
All articles ...
Subscriptions
Swing Trading Course
Account
Disclaimer
Affiliate
Contact
Privacy
ARGENX SE - ADR (ARGX) Stock News
USA
- NASDAQ:ARGX -
US04016X1019
-
ADR
829.83
USD
+12.51 (+1.53%)
Last: 10/27/2025, 8:03:36 PM
829.83
USD
0 (0%)
After Hours:
10/27/2025, 8:03:36 PM
Overview
Stock Chart
Technical Analysis
Fundamental Analysis
Analyst Ratings
Earnings Estimates
Financials
Ownership
News
ARGX Latest News, Press Relases and Analysis
All
Press Releases
4 days ago - By: Chartmill
ARGENX SE - ADR (NASDAQ:ARGX) Shows Strong Growth Traits Matching Navellier's Criteria
5 days ago - By: argenx SE
argenx to Report Third Quarter 2025 Financial Results and Business Update on October 30, 2025
5 days ago - By: argenx SE
argenx to Report Third Quarter 2025 Financial Results and Business Update on October 30, 2025
5 days ago - By: Benzinga
If You Invested $1000 In argenx Stock 5 Years Ago, You Would Have This Much Today
5 days ago - By: The Motley Fool
- Mentions:
TTD
AMZN
PEP
CELH
...
Checking In on The Trade Desk, Bristol Myers Squibb, and Other Stocks
13 days ago - By: argenx SE
argenx to Highlight Key Data and Breadth of Immunology Innovation at 2025 AANEM Annual Meeting and MGFA Scientific Session
13 days ago - By: argenx SE
argenx to Highlight Key Data and Breadth of Immunology Innovation at 2025 AANEM Annual Meeting and MGFA Scientific Session
15 days ago - By: Benzinga
How Do Investors Really Feel About argenx SE?
24 days ago - By: argenx SE
argenx announces Extraordinary General Meeting of Shareholders on November 18, 2025
24 days ago - By: argenx SE
argenx announces Extraordinary General Meeting of Shareholders on November 18, 2025
a month ago - By: Zacks Investment Research
- Mentions:
INCY
INCY vs. ARGX: Which Stock Is the Better Value Option?
a month ago - By: Zacks Investment Research
- Mentions:
HALO
ABBV
ANIP
AbbVie Seeks FDA Nod for Tavapadon to Treat Parkinson's Disease
a month ago - By: Investor's Business Daily
- Mentions:
XPH
PPH
XBI
IBB
...
Pharma Tariffs Back In Spotlight On New Trump Threat
2 months ago - By: Investor's Business Daily
- Mentions:
UTHR
AUPH
HALO
United Therapeutics Price Strength Rating Jumps After Its Stock Soared 33% Last Week On Positive Drug Test Results
2 months ago - By: Investor's Business Daily
- Mentions:
DNTH
AZN
SNY
Why Dianthus Therapeutics, Up 47% In Four Weeks, Just Surged Again
2 months ago - By: Zacks Investment Research
- Mentions:
KMDA
KMDA or ARGX: Which Is the Better Value Stock Right Now?
2 months ago - By: argenx SE
argenx to Present at Upcoming Investor Conferences
2 months ago - By: argenx SE
argenx to Present at Upcoming Investor Conferences
2 months ago - By: Investor's Business Daily
- Mentions:
AUPH
HALO
RIGL
Argenx Stock Hits Record High After Reporting 664% Earnings Surge; This Rating Upgraded
2 months ago - By: Yahoo Finance
- Mentions:
JPM
RJF
ALK
SYM
...
Figma initiated, Okta upgraded: Wall Street's top analyst calls
2 months ago - By: Investor's Business Daily
- Mentions:
RY
RY.CA
Argenx Tops Buy Point On Bullish Study, 850 Price Target
2 months ago - By: argenx SE
argenx Announces Positive Topline Results from ADAPT SERON Study of VYVGART in Patients with AChR-Ab Seronegative gMG
2 months ago - By: argenx SE
argenx Announces Positive Topline Results from ADAPT SERON Study of VYVGART in Patients with AChR-Ab Seronegative gMG
2 months ago - By: argenx SE
argenx to Host R&D Webinar Highlighting ARGX-119 on September 16, 2025
Please enable JavaScript to continue using this application.